特异性免疫治疗安全性.pptxVIP

特异性免疫治疗安全性福州儿童医院 唐素萍 国 外 研 究1 国 内 研 究2 临 床 体 会3过敏性疾病的有效治疗全球哮喘防治创议GINA变应性鼻炎及对哮喘的影响ARIA对症+对因的综合治疗方案对症用药的局限性The proportions of episode-free days in the fluticasone group and the placebo group were 96 percent and 89 percent during the last two months of the treatment period; and 84 percent and 87 percent during the last two months of the observation 。 单纯对症用药在停止治疗以后并不能长期改变疾病的进程，即 不能改变哮喘症状的发展及继续改善肺功能。 Guilbert TW,Morgan WJ,et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006 May 11;354(19):1985-97. 舌下含服 10年长期疗效观察 结论：对尘螨过敏的哮喘儿童进行4～5年舌下含服治疗终止后继续观